U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology
Tags:
Related News
Oil prices jumped to a three-week high as geopolitical tensions in the Middle East raised concerns about potential supply disruptions…
2 hours ago
Precious metals faced pressure today as the U.S. dollar gained strength following positive economic data from the Federal Reserve…
5 hours ago
Stay Ahead of Market Moves
Get our daily commodity market analysis delivered to your inbox. Join 5,000+ traders who trust our insights.
No spam. Unsubscribe anytime. 2x weekly digests.
Related Guides
Popular Articles
24k views
18K views
15K views